

REVIEW

Open Access



# Neuroimaging characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review

Zack Y. Shan<sup>1,2\*</sup>, Leighton R. Barnden<sup>2</sup>, Richard A. Kwiatek<sup>1</sup>, Sandeep Bhuta<sup>3</sup>, Daniel F. Hermens<sup>1</sup> and Jim Lagopoulos<sup>1</sup>

## Abstract

**Background:** Since the 1990s, neuroimaging has been utilised to study Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating illness with unknown aetiology. While brain abnormalities in ME/CFS have been identified, relatively little is known regarding which specific abnormalities are consistently observed across research groups and to what extent the observed abnormalities are reproducible.

**Method:** To identify consistent and inconsistent neuroimaging observations in ME/CFS, this retrospective and systematic review searched for studies in which neuroimaging was used to investigate brain abnormalities in ME/CFS in Ovid MEDLINE, PubMed (NCBI), and Scopus from January 1988 to July 2018. A qualitative synthesis of observations was performed to identify brain abnormalities that were consistently and inconsistently reported.

**Results:** 63 full-text articles were included in the synthesis of results from 291 identified papers. Additional brain area recruitment for cognitive tasks and abnormalities in the brain stem are frequent observations in 11 and 9 studies using different modalities from different research teams respectively. Also, sluggish blood oxygenation level-dependent (BOLD) signal responses to tasks, reduced serotonin transporters, and regional hypometabolism are consistent observations by more than two research teams. Single observations include abnormal brain tissue properties, regional metabolic abnormalities, and association of brain measures with ME/CFS symptoms. Reduced resting cerebral blood flow and volumetric brain changes are inconsistent observations across different studies.

**Conclusion:** Neuroimaging studies of ME/CFS have frequently observed additional brain area recruitment during cognitive tasks and abnormalities in the brain stem. The frequent observation of additional brain area recruitment and consistent observation of sluggish fMRI signal response suggest abnormal neurovascular coupling in ME/CFS.

**Keywords:** Chronic fatigue syndrome, Neuroimaging, Systematic review, Neurovascular coupling

## Background

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex and debilitating chronic illness. Patients with ME/CFS experience overwhelming fatigue that severely impacts their quality of life, with 25% of

ME/CFS patients chronically bedridden or house-bound. However, there is no known underlying disease process, no biologically based treatment, and no objective diagnostic criteria for ME/CFS.

Although the aetiology of ME/CFS remains unclear, the well-documented neurological symptoms, sleep and autonomic dysfunction, abnormalities in cognition, and altered sensory and pain perception, suggest that abnormal brain function assumes a crucial role in the underlying disease process [1]. Given the aforementioned

\*Correspondence: zshan@usc.edu.au

<sup>1</sup> Sunshine Coast Mind and Neuroscience Thompson Institute, University of the Sunshine Coast, Birtinya, QLD 4575, Australia  
Full list of author information is available at the end of the article



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

constellation of symptoms, ME/CFS has been classified as a neurological disease (ICD-10 G93.3; ICD-11 8E49) by the World Health Organization.

Researchers have used multiple neuroimaging techniques to explore structural, neurochemical, and functional brain changes in patients with ME/CFS since the 1990s. However, the results have been mixed for various reasons, such as small sample sizes and ill-defined disease classification. In short, it is recognised that abnormal brain function plays a critical role in ME/CFS. However, little is known about what abnormalities are consistently observed across multicentre studies and to what extent the observed abnormalities are reproducible. Therefore, there is a pressing need to summarise the consistency of observed abnormalities across studies in this field so as to inform future directions of neuroimaging research in ME/CFS.

This study systematically reviewed the neuroimaging studies of ME/CFS from January 1988 to July 2018 to specifically address the following three questions. (i) What structural or functional differences were consistently (i.e. by two or more research teams) observed in radiological brain imaging studies of ME/CFS? (ii) What brain measures were consistently associated with ME/CFS symptom phenotypes? (iii) What differences or symptoms and associated brain measures were inconsistently reported? The aim of this study was to facilitate a better-informed hypothesis of ME/CFS aetiology based on consistent findings, to reconcile some inconsistent findings, and to identify a future research focus.

## Methods

The objectives and analyses methods of this retrospective systematic review were specified in advance, documented and registered in the PROSPERO database [2]. The registration was submitted after the initial search but before the start of data extraction (examining contents of the selected papers).

### Data Source and Searches

An investigator (ZS) searched electronic databases, including Ovid MEDLINE, PubMed (NCBI), and Scopus, to identify relevant articles published between January 1988 (year of the first ME/CFS case definition) and July 2018. Cross-referencing supplemented the search during reviewing of full-text articles.

The search field included the title, abstract, and keywords with any combination of a population condition and an exposure condition as the search condition. The population condition included chronic fatigue syndrome, myalgic encephalomyelitis, systemic exertion intolerance disease, and their abbreviations. The exposure condition included neuroimage, neuroimaging,

magnetic resonance imaging (MRI), functional magnetic resonance imaging, diffusion tensor imaging, magnetic resonance spectroscopy, arterial spin labelling, diffusion-weighted imaging, computed tomography, position emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound, and their abbreviations.

### Study Selection

We included the following studies: (i) peer-reviewed English language scientific journal articles; (ii) ME/CFS definitions including systemic exertion intolerance disease proposed by Institute of Medicine [3], International Consensus Criteria [4], Paediatric ME/CFS definition [5], Canadian consensus criteria [6], Centers for Disease Control and Prevention (CDC) Holmes criteria [7], London criteria [8], Reeves criteria [9], CDC Fukuda criteria [10], Oxford criteria [11]; (iii) neuroimaging techniques of MRI, PET, SPECT, computed tomography (CT), ultrasound.

We excluded the following studies: (i) non-peer reviewed articles; (ii) articles not written in English; (iii) review, hypothesis without experimental data, editorial, and opinion articles, case reports and protocols, since this study is to summarise consistent observations; (iv) the modalities of electroencephalography, magnetoencephalography, and functional near-infrared spectroscopy because these techniques do not produce images and the scope of this study was limited to radiological brain imaging modalities.

Two investigators (ZS and LB) independently reviewed the abstract of each study to determine eligibility. Any disagreement was resolved by discussion to consensus.

### Risk of bias evaluation

The risk of bias for each study was evaluated using a tool adapted from QUADAS-2 [12], a quality assessment tool of diagnostic accuracy studies. This study reviewed observational studies; thus, the QUADAS-2 tool was adapted in 4 domains: (i) patient selection, (ii) index test, (iii) control standard, and (iv) control of confounding factors.

The signalling questions for the domain of patient selection included: (i) whether a consecutive or random sample of patients was enrolled; and (ii) whether the study avoided inappropriate exclusion.

The signalling questions for the domain of index test included: (i) whether a full brain imaging protocol was reported; and whether any potential bias existed in the protocol; (ii) whether a significance threshold was pre-specified and whether the multiple comparison correction was appropriately handled.

The signalling questions for the domain of control standard included: (i) whether controls have similar age as patients or were controlled for age; (ii) whether the control group had the same gender ratio as the patient group or were controlled for gender ratio and (iii) whether controls were selected or recruited from the same or a similar population.

The signalling questions for the domain of control of confounding factors included: (i) whether psychiatric disorders including anxiety and depression were screened or controlled for; (ii) whether obesity was screened for, or body mass index was controlled for and (iii) whether neurologically active medication was screened.

Each domain of a study was summarised as low risk (no signalling question violated), moderate risk (one signalling question violated), or high risk (more than one signalling questions violated). If a study had one or more domain with high risks, the study results were interpreted with caution and relevant to the violations.

### Synthesis of results

The following contents were extracted from each article: author details, affiliations, country, ME/CFS diagnostic criteria, number of participants, demographics, aim of paper, image modality, analysis method, and observations.

Extracted findings were classified as frequent, consistent, single, and inconsistent observations. The frequent, consistent, and single observations were defined as same or similar findings reported by five or more research teams, by two to four teams, and one research team without inconsistent finding reported, respectively. The inconsistent observations were defined as findings reported by one or more research teams with contradictory findings reported. Studies that had one common author and from the same institution were considered as studies from the same research team.

### Results

Among 291 records identified by searches, 215 records did not meet the inclusion criteria and were excluded upon screening based on abstract and title. The full-text articles of the remaining 76 records were reviewed. Subsequently, 16 articles were excluded based on exclusion criteria. Three new articles were identified in the citations during the review of the full-text articles and were thus added (Fig. 1). Finally, 63 full-text articles were included in the synthesis of results.

### Study characteristics

The reviewed studies have used ME/CFS diagnostic criteria including CDC-Holmes criteria [7], Oxford criteria [11], CDC-Fukuda criteria [10], Canadian consensus

criteria [6], Paediatric ME/CFS definition [5], Reeves criteria [9], and their combinations. Note that four studies [13–16] included in this review used a combination of CDC-Fukuda and Reeves criteria, another two studies [17, 18] used a combination of CDC-Holmes and Oxford criteria. The CDC-Fukuda definition is the most frequently used (54 out of 63 articles) criteria in the articles reviewed (Fig. 2a).

Although the number of articles published in recent years has appreciably increased (from approximate two articles per year before 2015 to six articles per year since), the overall number of radiological brain imaging studies of ME/CFS remains small with a maximum of 10 articles published in 2018 (Fig. 2b).

The sample size of the smaller group (patients or controls) in 40 out of the 63 articles reviewed were equal to or smaller than 16 (Fig. 2c). The total sample sizes (patients and controls) in 49 out of 63 articles reviewed were equal to or smaller than 53 (Fig. 2d).

The characteristics of ME/CFS diagnostic criteria, publication date, sample size, brain imaging modalities of each article are summarized in Additional file 1.


### Risk of bias

With the adapted QUADAS-2, 61 and 56 out of 63 reviewed articles complied with all signalling questions in the domain of patient selection and index test, respectively. In the domain of control standard, 37 articles violated one signalling question, and 11 articles violated two more signalling questions. In the domain of confounding factor control, 35 articles violated one signalling question, and 14 articles violated two or more signalling questions (Fig. 3). The risks of bias of each article are summarized in SI.

### Frequent observations

#### *Additional brain regions recruited for cognitive tasks in patients with ME/CFS*

A SPECT study reported that patients with ME/CFS presented more diffuse and less focal activation patterns than controls when performing the paced auditory serial addition test [19]. We identified 12 task functional MRI studies of ME/CFS [14, 16, 20–29]. Different patterns of blood oxygenation level-dependent (BOLD) signal changes associated with tasks were reported in each article (detailed in SI). Of these 12 studies, 10 articles reported that patients with ME/CFS either recruited additional brain regions or had a greater BOLD response than controls for cognitive tasks but with the same performance [16, 20–25, 27–29], although decreased BOLD activity was also reported in specific regions. Two remaining studies tested basal ganglia function [14] and reward sensitivity [26] and observed lower BOLD



changes in basal ganglia in gambling tasks [14] and lower BOLD changes in the putamen in low-reward condition gambling task [26].

#### **Abnormalities identified in the brain stem of patients with ME/CFS**



Five studies from two groups reported structural abnormalities in the brain stem in ME/CFS using MRI [30–34]. Additionally, higher binding potential values of  $^{11}\text{C}$ -(R)-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline-carboxamide, indicating local neuroinflammation, was observed in the brain stem in ME/CFS using PET [35]. Three studies reported hypoperfusion in the brain stem using  $^{99}\text{Tc}^{\text{m}}$ -hexamethyl-propylene-aminoxime ( $^{99}\text{Tc}^{\text{m}}$ -HMPAO) SPECT [17],  $^{11}\text{C}$  acetyl-L-carnitine PET [36], and 18-fluorodeoxyglucose (FDG) PET [37].

However, two  $^{99}\text{Tc}^{\text{m}}$ -HMPAO SPECT studies from another research group did not observe significant regional cerebral blood flow (CBF) differences in the brain stem in ME/CFS [38, 39].

#### **Consistent observations**

##### **Sluggish BOLD responses to tasks**

Shan et al. examined sample entropy, a measure of the complexity of physiological time-series signals, of BOLD signal changes associated with the Stroop task in ME/CFS [29]. BOLD sample entropies in 10 regions were significantly lower in ME/CFS and explained 56% of variances in the 36-item Short Form Health Survey scores [29]. Another fMRI study observed that responsiveness of the auditory cortex was attenuated in patients with ME/CFS. In addition, the rate of the attenuation was



positively correlated with the subjective sensation of fatigue [40].

**Reduction of serotonin transporters in ME/CFS**

A widespread reduction in the serotonin 1A receptor binding potential, particularly in the hippocampus bilaterally [41], and reduced serotonin transporters density in

the rostral subdivision of the anterior cingulate [42] were reported from two separate groups.

**Regional reduced FDG uptakes**

FDG PET from two different groups showed significant hypometabolism in the right mediofrontal cortex and brain stem [37] and in the orbitofrontal cortex [43].

## Single observations

### *Regional brain tissue characteristics*

Using radiologists' reporting, abnormal MRI scans were found to be correlated with low physical functions [44]; more abnormal scans were found in patients with ME/CFS but no psychiatric diagnosis, than in those with psychopathy and controls [45]; and patients with ME/CFS had more abnormal scans than healthy controls (HCs) [46]. Significantly different T1 weighted and T2 weighted spin echo signal intensities were found in various brain regions using voxel based comparison and regression analysis (detailed in SI) [30, 47, 48]. However, these abnormalities were distributed in different regions in different studies.

### *White Matter microstructure by diffusion tensor imaging*

Zeineh et al. observed a significant increase of fractional anisotropy accompanied by an increase in axial diffusivity and a decrease in radial diffusivity in the right anterior arcuate fasciculus in patients with ME/CFS [49].

### *Differences in brain metabolites*

Using MR spectroscopy, lower N-acetylaspartate concentration in the hippocampus [50], lower cortical glutathione levels [51, 52], higher choline concentration in the basal ganglia [53], higher lactate concentrations in the lateral ventricles (from a same group) [51, 52, 54–56], higher choline to creatine ratio in the occipital cortex [57] have been reported in ME/CFS. No differences in  $\gamma$ -aminobutyric acid nor glutamate + glutamine either in the occipital cortex or anterior cingulate cortex [55] or N-acetylaspartate to creatine ratio in the frontal and occipital cortex [57] have been reported. More pain was associated with a reduced N-acetylaspartate to creatine ratio, however, no group difference was found in the dorsolateral prefrontal cortex [15]. Yamamoto et al. reported that patients with ME/CFS and positive serum autoantibodies showed significantly lower brain muscarinic cholinergic receptor binding, although the acetylcholinesterase activity remained similar [58].

### *Intracranial compliance measured as a ratio of changes in intracranial volume and pressure during the cardiac circle*

There was no group difference, although low intracranial compliance and high cerebral perfusion were associated with increased severity of symptoms of orthostatic intolerance in patients with ME/CFS [59].

### *Association of cerebral vascular control with skeletal muscle pH in ME/CFS*

He et al. reported that cerebral vascular control measured by Valsalva manoeuvre fMRI is closely related to skeletal muscle pH both at rest and after dynamic stimulation in

ME/CFS [60]. However, this study did not include a HC group comparison [60].

## Inconsistent observations

### *Global grey matter (GM) and white matter (WM) volumes*

Five studies have reported no significant difference in global GM or WM volumes [31, 33, 47–49]. A one-year longitudinal study reported that the mean and the longitudinal change of cerebrospinal fluid (CSF) volume was not significantly different between ME/CFS patients and HCs [61]. De Lange et al. observed a reduction in total GM volumes but no difference in total WM volumes in ME/CFS [62]. Finkelmeyer et al. reported higher total GM and smaller WM volumes after accounting for total intracranial volume in ME/CFS [34].

### *Regional GM and WM volumes*

De Lange et al. reported that there was no significant difference in regional GM or WM volumes in ME/CFS [62]. Finkelmeyer et al. observed increased regional GM volumes in the amygdala and insula and decreased regional WM volume in the midbrain, pons, and right temporal lobe [34]. Two studies from different groups reported reduced regional GM volumes in various brain regions [63, 64]. A 6-years longitudinal study observed a significant decrease of WM volume in the left inferior fronto-occipital fasciculus (IFOF) in ME/CFS while it was unchanged in HCs [47]. Significantly lower WM volume in the left IFOF/arcuate was observed in a different sample by the same group [48]. Zeineh et al. observed significantly lower supratentorial WM volumes, statistically equivalent regional GM volumes and cortical thickness in the left hemisphere, and higher cortical thickness in the right lateral occipital, precentral, middle temporal, postcentral and pars orbitalis in ME/CFS [49]. Sevel et al. used a support vector machine based on 61 anatomical features (indices of area, thickness, and volume of cortical and subcortical structures) to classify ME/CFS with 79.58% accuracy [65].

### *Resting cerebral blood flow (CBF)*

Eight studies observed decreased global or regional CBF in ME/CFS [17, 18, 51, 52, 66–69]. Peterson et al. observed reduced cerebral perfusion in 3 of 10 at rest and 6 of 10 patients with ME/CFS after an exercise of walking 1.61 km/hour for 30 min while only in 2 of 10 HCs at rest and post-exercise [70]. However, another six studies observed no global or regional CBF difference [38, 59, 61, 71–73]. Fischler et al. observed three regions of interest (ROIs) with hypoperfusion and 9 ROIs with hyperperfusion out of 45 ROIs [39] in ME/CFS. Gay et al. observed no global CBF difference but reduced regional resting CBF in occipital and temporal lobes [74].

### Functional connectivity (FC)

Abnormal FC in the affective network, salience network, default mode network (DMN) were reported using ASL and fMRI [13, 28, 74–76]. Two resting state studies found increased FC in the DMN between posterior cingulate cortex (PCC) and ACC [13, 75] while two studies did not observe a FC difference between PCC and ACC [28, 74] in ME/CFS. Gay et al. observed reduced FC between PCC and ACC during cognitive tasks [74]. Two studies from the same research team observed reduced FC from the PCC to the salience network [74, 75].

### Discussion

The synthesis of the reviewed studies generated two frequent observations (larger recruitment of brain regions during cognitive tasks and abnormalities in the brain stem), three consistent observations (sluggish fMRI signal response to tasks, reduced serotonin transporters, and regional hypometabolism), and five single observations (regional T1 and T2 spin-echo intensity differences and abnormal clinical correlations, white matter microstructural changes, regional metabolite abnormalities, associations between intracranial compliance and severity of orthostatic intolerance symptoms, and associations between cerebral vascular control and skeletal muscle pH).

Larger recruitments of brain areas could be potentially explained by the sluggish BOLD response to tasks, which was observed consistently in two fMRI studies [29, 40]. The BOLD response is determined by neurovascular coupling (NVC) which consists of an initial feedforward mechanism of glutamate activation of a  $\text{Ca}^{2+}$  dependent signalling pathway in both neurons and astrocytes to release vasoactive factors to increase local blood flow, and secondary feedback driven by metabolism [77]. Several recent studies have demonstrated that  $\text{Ca}^{2+}$  mobilisation is impaired in ME/CFS from genetic [78, 79], molecular biological [80], and electrophysiological aspects [81]. These observations would suggest, it is plausible that glutamate- $\text{Ca}^{2+}$  NVC pathways in patients with ME/CFS may be impaired because of reduced TRPM3 activity and  $\text{Ca}^{2+}$  mobilisation.

Impaired NVC could have multiple detrimental effects on the brain. Firstly, deficits in matching local CBF to neuronal activity may lead to hypoxia. Secondly, inadequate energy supply to activated neurons may potentially lead to energy failure of ionic pumps. Thirdly, oxidative stress that impairs blood vessel endothelial cell function may cause blood–brain barrier (BBB) breakdown and neuroinflammation. These potential detrimental effects are generally diffuse and multifocal in the brain, leading to reduced cognitive efficiency in ME/CFS and manifesting as more extensive functional recruitment during

cognitive task performance. A similar manifestation has been observed in patients with other neuropathologies that result in diffuse damage such as traumatic brain injury [82]. Reduced cognitive efficiency may be the neurological underpinning of the observation that patients with ME/CFS often report subjective changes when performing cognitive tasks despite normal objective performance. Impaired NVC in ME/CFS is further supported by structural MRI observations of regional white matter loss in the left inferior fronto-occipital fasciculus [47] and the brain stem [30–34], both being brain regions sensitive to hypoxia [83, 84].

Dysfunction of NVC is closely related to neuroinflammation, which is another neurological disease process proposed to underly ME/CFS [85, 86]. Dysfunction of NVC may trigger neuroinflammation. The typical NVC dysfunction features of inflammatory and angiogenic activation triggered by hypoxia may jointly result in a leaky BBB, brain oedema, and neuronal dysfunction and damage [87]. Vice versa, neuroinflammation and infection may result in NVC dysfunction, whereby, activation of microglia, especially the formation of the M2 phenotype, exacerbates damage to the BBB. Neuroinflammation molecular patterns can interact with neurotransmitters, increase procoagulant activity and thrombosis, and cause endothelial injury and damage, resulting in NVC dysfunction [88]. Although there is no direct evidence to support either dysfunction of NVC or neuroinflammation as the primary aetiology factor of ME/CFS, we posit that dysfunction of NVC constitutes a critical underlying disease process in ME/CFS.

The synthesis of articles in this review also generated three consistent observations: sluggish BOLD response to task [29, 40], reduced serotonin transporter, and regional hypometabolism. The sluggish BOLD response is consistent with NVC dysfunction. Two studies observed reduced serotonin transporter in ME/CFS [41, 42]. Serotonergic imbalance is a prominent feature in major depression [89] and a large percentage of patients with ME/CFS experience depression. These observations may help explain the well documented depressive symptoms in ME/CFS. The evidence of regional hypometabolism [37, 43] is aligned with an NVC dysfunction. The hypoxia, oxidative stress, and energy deficiency caused by NVC dysfunction may lead to reduced glucose uptake and result in a vicious cycle [90]. The inconsistent observations of volumetric differences in ME/CFS are consistent with the notion that the detrimental effects of NVC dysfunctions are diffuse and multifocal in the brain. Different studies may generate positive or negative findings depending on the disease severity and patient selection.

This review noted ME/CFS as an under-recognised disease and that brain imaging studies of ME/CFS suffered

from small sample size. A small sample size not only reduces the chance of detecting a true effect but also reduces the likelihood that a statistically significant result reflects a true effect [91]. As such, we argue that there is a pressing need to establish a collaborative neuroimaging databank for ME/CFS in addition to a proposed ME/CFS biobank [92]. Notably, more than 80% of reviewed studies did not control for lifestyle differences. Physical activity may impact brain structures and functions [93, 94]. Given that patients with ME/CFS have to reduce their daily activities because of fatigue, objective measurement of physical activity in both patients and controls is essential to differentiate between brain differences that are unique in ME/CFS and those due to reduced physical activity.

This review was unable to perform a formal meta-analysis because: (i) There were few studies on neuroimaging of ME/CFS. (ii) Each study used an ad hoc analysis method. (iii) Different aspects were investigated in different studies. Nevertheless, this systematic review of neuroimaging in ME/CFS provides a snapshot of ME/CFS brain imaging studies to date and identifies deficiencies that need to be accounted for in future studies.

## Conclusion

We systematically reviewed 63 scientific articles on brain imaging studies of ME/CFS. The results of our qualitative synthesis of these articles are consistent with autonomic dysfunctions in ME/CFS, potentially arising centrally. In addition, this review highlighted that more extensive brain areas were recruited during cognitive tasks in patients with ME/CFS, which had not previously been well recognised. This feature may represent brain function inefficiency caused by an NVC dysfunction. This review also identified deficiencies in the previous neuroimaging studies in ME/CFS, including small sample sizes and lack of objective physical activity measurement in control groups. We advocate establishing a neuroimaging databank of ME/CFS to mitigate these issues.

## Supplementary information

**Supplementary information** accompanies this paper at <https://doi.org/10.1186/s12967-020-02506-6>.

Supplementary file1 (DOCX 401 kb)

## Abbreviations

ACC: Anterior cingulate cortex; BBB: Blood–brain barrier; BOLD: Blood oxygenation level-dependent; CBF: Cerebral blood flow; CDC: Centers for Disease Control and Prevention; DMN: Default mode network; FC: Functional connectivity; FDG: 8-fluorodeoxyglucose; GM: Grey matter; HC: Health control; ME/CFS: Myalgic encephalomyelitis/chronic fatigue syndrome; NVC: Neurovascular coupling; PCC: Posterior cingulate cortex; SI: Support Information; WM: White matter.

## Acknowledgements

Not applicable.

## Authors' contributions

ZYS conceptualised and designed the study. ZYS and LRB analysed the data. All author contributed to interpretation of results and drafting the manuscript and approved publication. All authors read and approved the final manuscript.

## Funding

This study was supported by The Judith Jane Mason & Harold Stannett Williams Memorial Foundation. The financial support did not affect any aspect of the study.

## Availability of data and materials

The articles reviewed in this study are available in the public domain.

## Ethics approval and consent to participate

This manuscript is strictly a systematic review of published articles; therefore, ethics approval and consent to participate is not applicable.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup> Sunshine Coast Mind and Neuroscience Thompson Institute, University of the Sunshine Coast, Birtinya, QLD 4575, Australia. <sup>2</sup> National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Southport, QLD 4222, Australia. <sup>3</sup> Medical Imaging Department, Gold Coast University Hospital, Parklands, QLD 4215, Australia.

Received: 9 April 2020 Accepted: 26 August 2020

Published online: 01 September 2020

## References

- Holgate S, Komaroff A, Mangan D, Wessely S. Chronic fatigue syndrome: understanding a complex illness. *Nat Rev Neurosci*. 2011;12:539–44.
- Shan Z, Barnden L. Neuroimaging observations of brain differences in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) from normal controls: a systematic review. PROSPERO 2019 CRD42019136879 [[https://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD42019136879](https://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019136879)]
- Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine: *Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness*. National Academies Press; 2015.
- Carruthers B, van de Sande M, DeMeirleir K, Klimas N, Broderick G, Mitchell T, Staines D, Powles A, Speight N, Vallings R, et al. Myalgic encephalomyelitis: International Consensus Criteria. *J Intern Med*. 2011;270:327–38.
- Jason LA, Porter N, Shelleby E, Bell DS, Lapp CW, Rowe K, De Meirleir K. A case definition for children with Myalgic Encephalomyelitis/chronic fatigue syndrome. *Clin Med Pediatr*. 2008;1:S978.
- Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, Basted AC, Flor-Henry P, Joshi P, Powles AP. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. *J Chronic Fatigue Syndr*. 2003;11:7–115.
- Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JF, Dubois RE, Cunningham-Rundles C, Pahwa S, et al. Chronic fatigue syndrome: a working case definition. *Ann Intern Med*. 1988;108:387–9.
- Goudsmit E, Shepherd C, Dancy C, Howes S. ME: Chronic fatigue syndrome or a distinct clinical entity. *Health Psychol Update*. 2009;18:26–33.
- Reeves WC, Wagner D, Nisenbaum R, Jones JF, Gurbaxani B, Solomon L, Papanicolaou DA, Unger ER, Vernon SD, Heim C. Chronic fatigue syndrome—a clinically empirical approach to its definition and study. *BMC Med*. 2005;3:19.

10. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. *Ann Intern Med*. 1994;121:953–9.
11. Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A, Edwards RH, Hawton KE, Lambert HP, Lane RJ, et al. A report—chronic fatigue syndrome: guidelines for research. *J R Soc Med*. 1991;84:118–21.
12. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med*. 2011;155:529–36.
13. Kim BH, Namkoong K, Kim JJ, Lee S, Yoon KJ, Choi M, Jung YC. Altered resting-state functional connectivity in women with chronic fatigue syndrome. *Psychiatry Res Neuroimag*. 2015;234:292–7.
14. Miller AH, Jones JF, Drake DF, Tian H, Unger ER, Pagnoni G. Decreased basal ganglia activation in subjects with chronic fatigue syndrome: association with symptoms of fatigue. *PLoS ONE*. 2014;9:e98156.
15. van der Schaaf ME, De Lange FP, Schmits IC, Geurts DEM, Roelofs K, van der Meer JWM, Toni I, Knoop H. Prefrontal structure varies as a function of pain symptoms in chronic fatigue syndrome. *Biol Psychiat*. 2017;81:358–65.
16. van der Schaaf ME, Roelofs K, de Lange FP, Geurts DEM, van der Meer JWM, Knoop H, Toni I. Fatigue is associated with altered monitoring and preparation of physical effort in patients with chronic fatigue syndrome. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2018;3:392–404.
17. Costa DC, Tannock C, Brostoff J. Brainstem perfusion is impaired in chronic fatigue syndrome. *QJM*. 1995;88:767–73.
18. Schwartz RB, Garada BM, Komaroff AL, Tice HM, Gleit M, Jolesz FA, Holman BL. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. *AJR Am J Roentgenol*. 1994;162:935–41.
19. Schmalig KB, Lewis DH, Fiedelak JI, Mahurin R, Buchwald DS. Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. *Psychosom Med*. 2003;65:129–36.
20. Caseras X, Mataix-Cols D, Giampietro V, Rimes KA, Brammer M, Zelaya F, Chalder T, Godfrey EL. Probing the working memory system in chronic fatigue syndrome: a functional magnetic resonance imaging study using the n-back task. *Psychosom Med*. 2006;68:947–55.
21. Caseras X, Mataix-Cols D, Rimes KA, Giampietro V, Brammer M, Zelaya F, Chalder T, Godfrey E. The neural correlates of fatigue: an exploratory imaginal fatigue provocation study in chronic fatigue syndrome. *Psychol Med*. 2008;38:941–51.
22. Cook DB, Light AR, Light KC, Broderick G, Shields MR, Dougherty RJ, Meyer JD, VanRiper S, Stegner AJ, Ellingson LD, Vernon SD. Neural consequences of post-exertion malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Brain Behav Immun*. 2017;62:87–99.
23. Cook DB, O'Connor PJ, Lange G, Steffener J. Functional neuroimaging correlates of mental fatigue induced by cognition among chronic fatigue syndrome patients and controls. *Neuroimage*. 2007;36:108–22.
24. De Lange FP, Kalkman JS, Bleijenberg G, Hagoort P, Werf SPV, Van Der Meer JWM, Toni I. Neural correlates of the chronic fatigue syndrome - An fMRI study. *Brain*. 2004;127:1948–57.
25. Lange G, Steffener J, Cook DB, Bly BM, Christodoulou C, Liu WC, DeLuca J, Natelson BH. Objective evidence of cognitive complaints in Chronic Fatigue Syndrome: a BOLD fMRI study of verbal working memory. *Neuroimage*. 2005;26:513–24.
26. Mizuno K, Kawatani J, Tajima K, Sasaki AT, Yoneda T, Komi M, Hirai T, Tomoda A, Joudoi T, Watanabe Y. Low putamen activity associated with poor reward sensitivity in childhood chronic fatigue syndrome. *Neuroimage Clin*. 2016;12:600–6.
27. Mizuno K, Tanaka M, Tanabe HC, Joudoi T, Kawatani J, Shigihara Y, Tomoda A, Miike T, Imai-Matsumura K, Sadato N, Watanabe Y. Less efficient and costly processes of frontal cortex in childhood chronic fatigue syndrome. *Neuroimage Clin*. 2015;9:355–68.
28. Shan ZY, Finegan K, Bhuta S, Ireland T, Staines DR, Marshall-Gradisnik SM, Barnden LR. Decreased connectivity and increased blood oxygenation level dependent complexity in the default mode network in individuals with Chronic Fatigue Syndrome. *Brain Connectivity*. 2018;8:33–9.
29. Shan ZY, Finegan K, Bhuta S, Ireland T, Staines DR, Marshall-Gradisnik SM, Barnden LR. Brain function characteristics of chronic fatigue syndrome: A task fMRI study. *Neuroimage Clin*. 2018;19:279–86.
30. Barnden LR, Crouch B, Kwiatek R, Burnet R, Del Fante P. Evidence in chronic fatigue syndrome for severity-dependent upregulation of prefrontal myelination that is independent of anxiety and depression. *NMR Biomed*. 2015;28:404–13.
31. Barnden LR, Crouch B, Kwiatek R, Burnet R, Mernone A, Chrystidis S, Scroop G, Del Fante P. A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. *NMR Biomed*. 2011;24:1302–12.
32. Barnden LR, Kwiatek R, Crouch B, Burnet R, Del Fante P. Autonomic correlations with MRI are abnormal in the brainstem vasomotor centre in Chronic Fatigue Syndrome. *Neuroimage Clin*. 2016;11:530–7.
33. Barnden LR, Shan ZY, Staines DR, Marshall-Gradisnik S, Finegan K, Ireland T, Bhuta S. Hyperintense sensorimotor T1 spin echo MRI is associated with brainstem abnormality in chronic fatigue syndrome. *Neuroimage Clin*. 2018;20:102–9.
34. Finkelmeyer A, He J, Maclachlan L, Watson S, Gallagher P, Newton JL, Blamire AM. Grey and white matter differences in Chronic Fatigue Syndrome: a voxel-based morphometry study. *Neuroimage Clin*. 2018;17:24–30.
35. Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, Tazawa S, Onoe K, Fukuda S, Kawabe J, Takahashi K, et al. Neuroinflammation in patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: an 11C-(R)-PK11195 PET study. *J Nucl Med*. 2014;55:945–50.
36. Kuratsune H, Yamaguti K, Lindh G, Evengard B, Hagberg G, Matsumura K, Iwase M, Onoe H, Takahashi M, Machii T, et al. Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. *Neuroimage*. 2002;17:1256–65.
37. Tirelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, Ferlin G. Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. *Am J Med*. 1998;105:545–85.
38. Fischler B, D'haenen H, Cluydts R, Michiels V, Michiels V, Demets K, Kaufman L, De Meirleir K. Comparison of 99mTc HMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow. *Neuropsychobiology*. 1996;34:175–83.
39. Fischler B, Flamen P, Everaert H, Bossuyt A, De Meirleir K. Physiological significance of 99mTc HMPAO SPECT scan anomalies in chronic fatigue syndrome: a replication study. *J Chronic Fatigue Syndr*. 1998;4:15–30.
40. Tanaka M, Sadato N, Okada T, Mizuno K, Sasabe T, Tanabe HC, Saito DN, Onoe H, Kuratsune H, Watanabe Y. Reduced responsiveness is an essential feature of chronic fatigue syndrome: A fMRI study. *BMC Neurol*. 2006;6:1–15.
41. Cleare AJ, Messa C, Rabiner EA, Grasby PM. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. *Biol Psychiat*. 2005;57:239–46.
42. Yamamoto S, Ouchi Y, Onoe H, Yoshikawa E, Tsukada H, Takahashi H, Iwase M, Yamaguti K, Kuratsune H, Watanabe Y. Reduction of serotonin transporters of patients with chronic fatigue syndrome. *NeuroReport*. 2004;15:2571–4.
43. Siessmeier T, Nix WA, Hardt J, Schreckenberger M, Egle UT, Bartenstein P. Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. *J Neurol Neurosurg Psychiatry*. 2003;74:922–8.
44. Cook DB, Lange G, DeLuca J, Natelson BH. Relationship of brain MRI abnormalities and physical functional status in chronic fatigue syndrome. *Int J Neurosci*. 2001;107:1–6.
45. Lange G, DeLuca J, Maldjian JA, Lee H, Tiersky LA, Natelson BH. Brain MRI abnormalities exist in a subset of patients with chronic fatigue syndrome. *J Neurol Sci*. 1999;171:3–7.
46. Natelson BH, Cohen JM, Brassloff I, Lee HJ. A controlled study of brain magnetic resonance imaging in patients with the chronic fatigue syndrome. *J Neurol Sci*. 1993;120:213–7.
47. Shan ZY, Kwiatek R, Burnet R, Del Fante P, Staines DR, Marshall-Gradisnik SM, Barnden LR. Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study. *J Magn Reson Imaging*. 2016;44:1301–11.
48. Shan ZY, Kwiatek R, Burnet R, Del Fante P, Staines DR, Marshall-Gradisnik SM, Barnden LR. Medial prefrontal cortex deficits correlate with unrefreshing sleep in patients with chronic fatigue syndrome. *NMR Biomed*. 2017;30:e3757.

49. Zeineh MM, Kang J, Atlas SW, Raman MM, Reiss AL, Norris JL, Valencia I, Montoya JG. Right arcuate fasciculus abnormality in chronic fatigue syndrome. *Radiology*. 2015;274:517–26.
50. Brooks JC, Roberts N, Whitehouse G, Majeed T. Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. *Br J Radiol*. 2000;73:1206–8.
51. Shungu DC, Weiduschat N, Murrrough JW, Mao X, Pillemer S, Dyke JP, Medow MS, Natelson BH, Stewart JM, Mathew SJ. Increased ventricular lactate in chronic fatigue syndrome III Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. *NMR Biomed*. 2012;25:1073–87.
52. Natelson BH, Mao X, Stegner AJ, Lange G, Vu D, Blate M, Kang G, Soto E, Kapusuz T, Shungu DC. Multimodal and simultaneous assessments of brain and spinal fluid abnormalities in chronic fatigue syndrome and the effects of psychiatric comorbidity. *J Neurol Sci*. 2017;375:411–6.
53. Chaudhuri A, Condon BR, Gow JW, Brennan D, Hadley DM. Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. *NeuroReport*. 2003;14:225–8.
54. Mathew SJ, Mao X, Keegan KA, Levine SM, Smith EL, Heier LA, Otchereko V, Coplan JD, Shungu DC. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. *NMR Biomed*. 2009;22:251–8.
55. Murrrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P, Levine SM, Mathew SJ, Shungu DC. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. *NMR Biomed*. 2010;23:643–50.
56. Natelson BH, Vu D, Coplan JD, Mao X, Blate M, Kang G, Soto E, Kapusuz T, Shungu DC. Elevations of ventricular lactate levels occur in both Chronic Fatigue Syndrome and Fibromyalgia. *Fatigue*. 2017;5:15–20.
57. Puri BK, Counsell SJ, Zaman R, Main J, Collins AG, Hajnal JV, Davey NJ. Relative increase in choline in the occipital cortex in chronic fatigue syndrome. *Acta Psychiatr Scand*. 2002;106:224–6.
58. Yamamoto S, Ouchi Y, Nakatsuka D, Tahara T, Mizuno K, Tajima S, Onoe H, Yoshikawa E, Tsukada H, Iwase M, et al. Reduction of [11C](+)-3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor. *PLoS ONE*. 2012;7:e51515.
59. Finkelmeyer A, He J, MacLachlan L, Blamire AM, Newton JL. Intracranial compliance is associated with symptoms of orthostatic intolerance in chronic fatigue syndrome. *PLoS ONE*. 2018;13:e0200068.
60. He J, Hollingsworth KG, Newton JL, Blamire AM. Cerebral vascular control is associated with skeletal muscle pH in chronic fatigue syndrome patients both at rest and during dynamic stimulation. *Neuroimage Clin*. 2013;2:168–73.
61. Perrin R, Embleton K, Pentreath VW, Jackson A. Longitudinal MRI shows no cerebral abnormality in chronic fatigue syndrome. *Br J Radiol*. 2010;83:419–23.
62. De Lange FP, Kalkman JS, Bleijenberg G, Hagoort P, Van Der Meer JWM, Toni I. Gray matter volume reduction in the chronic fatigue syndrome. *NeuroImage*. 2005;26:777–81.
63. Okada T, Tanaka M, Kuratsune H, Watanabe Y, Sadato N. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome. *BMC Neurol*. 2004;4:14.
64. Puri BK, Jakeman PM, Agour M, Gunatilake KD, Fernando KA, Gurusinge AI, Treasaden IH, Waldman AD, Gishen P. Regional grey and white matter volumetric changes in myalgic encephalomyelitis (chronic fatigue syndrome): a voxel-based morphometry 3 T MRI study. *Br J Radiol*. 2012;85:e270–273.
65. Sevel LS, Boissoneault J, Letzen JE, Robinson ME, Staud R. Structural brain changes versus self-report: machine-learning classification of chronic fatigue syndrome patients. *Exp Brain Res*. 2018;236:2245–53.
66. Biswal B, Kunwar P, Natelson BH. Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. *J Neurol Sci*. 2011;301:9–11.
67. Goldberg MJ, Mena I, Darcourt J. NeuroSPECT findings in children with chronic fatigue syndrome. *J Chronic Fatigue Syndr*. 1997;3:61–7.
68. Ichise M, Salit IE, Abbey SE, Chung DG, Gray B, Kirsh JC, Freedman M. Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. *Nucl Med Commun*. 1992;13:767–72.
69. Yoshiuchi K, Farkas J, Natelson BH. Patients with chronic fatigue syndrome have reduced absolute cortical blood flow. *Clin Physiol Funct Imaging*. 2006;26:83–6.
70. Peterson PK, Sirt SA, Grammich FC, Schenck CH, Pheley AM, Hu S, Chao CC. Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients. *Clin Diagn Lab Immunol*. 1994;1:222–6.
71. Boissoneault J, Letzen J, Robinson M, Staud R. Cerebral blood flow and heart rate variability predict fatigue severity in patients with chronic fatigue syndrome. *Brain Imag Behav*. 2018;31:31.
72. Lewis DH, Mayberg HS, Fischer ME, Goldberg J, Ashton S, Graham MM, Buchwald D. Monozygotic twins discordant for chronic fatigue syndrome: regional cerebral blood flow SPECT. *Radiology*. 2001;219:766–73.
73. Staud R, Boissoneault J, Craggs JG, Lai S, Robinson ME. Task related cerebral blood flow changes of patients with chronic fatigue syndrome: an arterial spin labeling study. *Fatigue*. 2018;6:63–79.
74. Gay CW, Robinson ME, Lai S, O'Shea A, Craggs JG, Price DD, Staud R. Abnormal resting-state functional connectivity in patients with chronic fatigue syndrome: results of seed and data-driven analyses. *Brain Connect*. 2016;6:48–56.
75. Boissoneault J, Letzen J, Lai S, O'Shea A, Craggs J, Robinson ME, Staud R. Abnormal resting state functional connectivity in patients with chronic fatigue syndrome: an arterial spin-labeling fMRI study. *Magn Reson Imaging*. 2016;34:603–8.
76. Boissoneault J, Letzen J, Lai S, Robinson ME, Staud R. Static and dynamic functional connectivity in patients with chronic fatigue syndrome: use of arterial spin labelling fMRI. *Clin Physiol Funct Imaging*. 2018;38:128–37.
77. Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. *Neuron*. 2017;96:17–42.
78. Marshall-Gradisnik S, Chacko A, Johnston S, Smith P, Nilius B, Staines D. Genotype frequencies of transient receptor potential melastatin M3 ion channels and acetylcholine muscarinic M3 receptor gene polymorphisms in chronic fatigue syndrome/myalgic encephalomyelitis patients. *Immunol Immunogenet Insights*. 2016;8:1.
79. Marshall-Gradisnik S, Huth T, Chacko A, Johnston S, Smith P, Staines D. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. *Appl Clin Genet*. 2016;9:39–47.
80. Nguyen T, Johnston S, Clarke L, Smith P, Staines D, Marshall-Gradisnik S. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels. *Clin Exp Immunol*. 2017;187:284–93.
81. Cabanas H, Muraki K, Eaton N, Balinas C, Staines D, Marshall-Gradisnik S. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. *Mol Med*. 2018;24:44.
82. Turner GR, Levine B. Augmented neural activity during executive control processing following diffuse axonal injury. *Neurology*. 2008;71:812–8.
83. Maillard P, Seshadri S, Beiser A, Himali JJ, Au R, Fletcher E, Carmichael O, Wolf PA, DeCarli C. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. *Lancet Neurol*. 2012;11:1039–47.
84. Marina N, Ang R, Machhada A, Kasymov V, Karagiannis A, Hosford PS, Mosenko V, Teschemacher AG, Vihko P, Paton JF, et al. Brainstem hypoxia contributes to the development of hypertension in the spontaneously hypertensive rat. *Hypertension*. 2015;65:775–83.
85. Komaroff AL. Inflammation correlates with symptoms in chronic fatigue syndrome. *Proc Natl Acad Sci USA*. 2017;114:8914–6.
86. Komaroff AL. Advances in understanding the pathophysiology of Chronic Fatigue Syndrome. *JAMA*. 2019;322(6):499–500.
87. Stanimirovic DB, Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence? *J Cereb Blood Flow Metab*. 2012;32:1207–21.
88. Tohidpour A, Morgun AV, Boitsova EB, Malinovskaya NA, Martynova GP, Khilazheva ED, Kopylevich NV, Gertsog GE, Salmina AB. Neuroinflammation and Infection: Molecular Mechanisms Associated with Dysfunction of Neurovascular Unit. *Front Cell Infect Microbiol*. 2017;7:276.
89. Kraus C, Castren E, Kasper S, Lanzemberger R. Serotonin and neuroplasticity - Links between molecular, functional and structural pathophysiology in depression. *Neurosci Biobehav Rev*. 2017;77:317–26.

90. Zilberter Y, Zilberter M. The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction. *J Neurosci Res*. 2017;95:2217–35.
91. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR. Power failure: why small sample size undermines the reliability of neuroscience. *Nat Rev Neurosci*. 2013;14:365–76.
92. Lacerda EM, Mudie K, Kingdon CC, Butterworth JD, O'Boyle S, Nacul L. The UK ME/CFS Biobank: a disease-specific biobank for advancing clinical research into myalgic encephalomyelitis/chronic fatigue syndrome. *Front Neurol*. 2018;9:1026.
93. Hamer M, Sharma N, Batty GD. Association of objectively measured physical activity with brain structure: UK Biobank study. *J Intern Med*. 2018;284:439–43.
94. Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. *Nat Rev Neurosci*. 2008;9:58–655.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

